Arcturus Therapeutics Holdings (ARCT) Non-Current Deffered Revenue (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has 8 years of Non-Current Deffered Revenue data on file, last reported at $4.2 million in Q3 2025.

• Quarterly Non-Current Deffered Revenue fell 68.36% year-over-year to $4.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.2 million (down 68.36% YoY) and the FY2024 annual result came in at $12.6 million, down 70.34% from the prior year.
• Non-Current Deffered Revenue slipped to $4.2 million in Q3 2025, from $8.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $42.5 million in Q4 2023 to a low of $4.2 million in Q3 2025.
• A 5-year average of $15.2 million and a median of $11.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue soared 709.25% — and 2024, when it sank 70.34%.
• Tracing ARCT's Non-Current Deffered Revenue over 5 years: stood at $19.9 million in 2021, then grew by 0.7% to $20.1 million in 2022, then surged by 111.73% to $42.5 million in 2023, then slumped by 70.34% to $12.6 million in 2024, then tumbled by 66.52% to $4.2 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $4.2 million (Q3 2025), $8.8 million (Q2 2025), and $9.6 million (Q1 2025), per Business Quant data.